Thursday, January 21, 2021 1:42:00 PM
https://emerginggrowth.com/stocks-involved-in-covid-19-testing-could-be-the-all-out-winners/
Another solid player in the COVID-19 test kit market is Avalon GloboCare (NASDAQ: AVCO) who recently partnered with Adial Pharmaceuticals (NASDAQ: ADIL) announcing a Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices.
Adial has granted Avalon non-exclusive, sub-distribution rights worldwide. As a result of the FDA’s EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors’ offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional. The FaStep COVID-19 IgG/IgM Rapid Test Devices are lateral flow assay, 10-minute, ‘instant,’ POC test devices for the qualitative detection of lgG and lgM antibodies specific to SARS-CoV-2 virus in fingerstick whole blood, venous whole blood, serum, and plasma. During testing, the specimen reacts with antigen coated particles in the test cassette after droplets of blood from the subject are placed on the cassette’s coated membrane.
“We believe there is significant market potential for these differentiated test kits, as these tests are able to detect IgG antibodies at a 98.6% accuracy and IgM antibodies at a 92.9% accuracy and provide results within 10-minutes,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our goal is to leverage our international distribution network and channel partners to bring the product to market globally.”
Google Ads
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s President and CEO, David Jin, M.D., Ph.D., highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr. Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial (Avalon feature in Biopharma Dealmakers).
“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.
Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology with lots of shots on goal when it comes to battling the COVID-19 pandemic including an FDA EUA approved rapid test kit, an intranasal vaccine, and a blood filtration system that is used to fight the cytokine storm in not only COVID-19 but certain cancers as well.
Avalon has a competitive advantage with their “S-Layer” technology in a vaccine market that is expected to grow to approximately 93.billion by 2026 according to Forbes business . This small cap biotechnology company is working towards the goal of changing the way we fight the devastating affects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant. With more upcoming catalysts in Q4 2020 and early 2021, it is safe to say that there is a large potential upside in AVCO’s stock that currently trades at only $1.17. The company has been well capitalized to date and has very clean cap table relative to its industry peers making it an attractive investment.
Recent ALBT News
- Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 04/22/2024 01:00:00 PM
- Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:49:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:30:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:30:46 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/20/2023 08:18:23 PM
- Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 08:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 01:15:01 PM
- Apple Approves Use of Avalon GloboCare’s KetoAir Mobile Application • GlobeNewswire Inc. • 10/04/2023 01:00:00 PM
- Avalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device • GlobeNewswire Inc. • 09/13/2023 01:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/08/2023 09:19:22 PM
- News Brief: Avalon GloboCare Corp. • AllPennyStocks.com • 09/05/2023 03:46:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2023 12:56:24 PM
- Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT) • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- News Brief: Avalon GloboCare Corp. • AllPennyStocks.com • 08/30/2023 02:26:00 PM
- Avalon’s Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis • GlobeNewswire Inc. • 08/30/2023 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/29/2023 08:55:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 01:11:56 PM
- Avalon’s Laboratory Services MSO Announces Expansion into Arizona • GlobeNewswire Inc. • 08/21/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:40:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 01:05:08 PM
- Avalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth • GlobeNewswire Inc. • 07/24/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM